Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Samarium-153-EDTMP in bone metastases

A Ahonen1, H Joensuu, J Hiltunen

  • 1Department of Clinical Chemistry, Oulu University Central Hospital, Finland.

Journal of Nuclear Biology and Medicine (Turin, Italy : 1991)
|December 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors.

ESMO open·2026
Same author

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST).

ESMO open·2021

Samarium-153 ethylenediaminetetramethylene phosphonate (153Sm-EDTMP) effectively palliates pain from bone metastases. Most patients experienced significant pain relief with minimal side effects, suggesting higher doses may be safe.

Area of Science:

  • Nuclear medicine
  • Oncology
  • Radiopharmacology

Background:

  • Bone metastases cause significant pain and reduced quality of life.
  • Effective palliative treatments for bone metastases are crucial.

Purpose of the Study:

  • To evaluate the efficacy and safety of 153Sm-EDTMP for pain relief in patients with bone metastases.
  • To assess the pharmacokinetics and biodistribution of 153Sm-EDTMP.

Main Methods:

  • A clinical trial involving 35 patients with painful bone metastases.
  • Single intravenous dose administration of 153Sm-EDTMP (330–1110 MBq).
  • Pain assessment, pharmacokinetic analysis, and biodistribution studies.

Main Results:

  • 80% of patients experienced detectable pain palliation; 54% reported substantial or complete relief.

Related Experiment Videos

  • Pain relief onset within one week, lasting 2–17 weeks.
  • Rapid blood clearance (<1% at 4 hours), complete urinary excretion by 6 hours, and no extra-skeletal accumulation.
  • Moderate myelosuppression (WHO grade III) in one patient; no clear dose-response due to small sample size.
  • Similar biodistribution to 99mTc-DPD, enabling bone scanning for patient selection.

    • Conclusions:

    • 153Sm-EDTMP is an effective agent for palliative treatment of painful bone metastases.
    • The drug demonstrates favorable pharmacokinetics with rapid clearance and minimal toxicity.
    • Higher doses of 153Sm-EDTMP may be safely administered without irreversible myelosuppression.